Clinical Trial Update: Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates for tocilizumab in steroid-refractory acute graft-versus-host disease (Phase 1/Phase 2) has terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Acute Graft Versus Host Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-01-31